Gian Life Care
- Market cap
- ₹ 4 Cr.
- P/E
- 5.7x
- P/B
- 0.23x
- 52-week range
- 3.93 – 13.23
- ROE
- 0%
- ROCE
- 2.4%
- Dividend yield
- 0%
- Debt / equity
- 0.3
- Sector
- Healthcare Services
- Industry
- Healthcare Service Provider
- Listed on
- BSE
About
Gian Life Care Limited is an India-based pathology provider. The Company is engaged in the business of providing diagnostic and related healthcare tests and services in various cities connecting Kanpur and nearby areas. The Company offers a range of approximately 1,344 tests, which includes various tests ranging from biochemistry, clinical pathology, coagulation, cytogenetics, cytology and hematology, among others. It is mainly engaged in the business of pathological investigations. The Company provides a range of diagnostic and related healthcare tests and services, such as patient diagnosis, prevention and wellness diagnosis services to its patients and healthcare providers. The Company is focused on opening several diagnostics labs in various parts of the state. Its subsidiaries include Gian Path Lab (India) Pvt Ltd and Gian Satguru Pathology LLP. Its customers include individual patients, hospitals, other healthcare providers and corporate customers.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Service Provider: 36 companies →Gian Life Care against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)5.7 against a typical 21: cheaper than most peers (1st = cheapest).3rd of 34
- Sales growth−29.6% against a typical +19.1% from a year earlier.30th of 31
- Profit growth−71.4% against a typical +25.2% from a year earlier.21st of 24
- Share price, 3 months−14.1% against a typical −7.7%.24th of 33
- Size₹ 4.3 Cr. market value against a typical ₹ 83 Cr. (1st = largest).34th of 34
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2 | 2 | 2 | 4 | 5 | 2 | 2 | 2 | 1 | 1 | 1 | 1 |
| Expenses | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
| Operating Profit | −1 | 1 | 0 | 2 | 3 | 0 | 0 | 0 | −0 | 0 | −0 | 0 |
| OPM % | −49% | 21% | 14.4% | 58.1% | 66.3% | 11.1% | 10.8% | 29.6% | −0.9% | 14.9% | −62.1% | 22.3% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | −1 | 0 | 0 | 2 | 3 | 0 | 0 | 0 | −1 | 0 | −1 | 0 |
| Tax % | 17.3% | 35% | 16.7% | 25.4% | 29.5% | 40% | 14.3% | 10.3% | −7.7% | 37.5% | −7.3% | −37.5% |
| Net Profit | −1 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | −1 | 0 | −1 | 0 |
| EPS in Rs | −0.92 | 0.25 | 0.19 | 1.5 | 2.06 | 0.09 | 0.12 | 0.34 | −0.58 | 0.05 | −0.49 | 0.1 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- −27%
- TTM
- −63%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- −136%
- 10 Years
- —
- 5 Years
- −37%
- 3 Years
- −41%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 10%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Gian Life Care | ₹ 4.20 | ₹ 4 Cr. | 5.7x | 0.2x | 0% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 65.8x | 13.6x | 22% | 7.8% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 70.9x | 9.8x | 14.3% | 17.2% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 67.8x | 7.3x | 11.1% | 11.7% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 100x | 9x | 9.7% | 9.2% |
| Narayana Hrudayalaya | ₹ 1,667.25 | ₹ 33,862 Cr. | 46.6x | 8.8x | 19.9% | 10.3% |
Management
- Avani Gupta
- Chief Financial Officer
- Vanshul Asnani
- Compliance Officer, Company Secretary
- Arun Kumar Gupta
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.